News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Revokes Orphan Drug Status of Altus Pharmaceuticals Inc.'s Pancreatic Insufficiency Treatment Candidate
July 4, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK (AP) - Biotechnology company Altus Pharmaceuticals Inc. said Tuesday the Food and Drug Administration revoked orphan drug status for the company's pancreatic insufficiency treatment.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
·
3 min read
·
Jennifer Smith-Parker
Regulatory
In Change That Pushed Pazdur Out, FDA May Lower Clinical Trial Requirements
December 5, 2025
·
2 min read
·
Dan Samorodnitsky
Regulatory
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals
December 5, 2025
·
2 min read
·
Tristan Manalac
Vaccines
CDC’s Vaccine Committee Recommends Delaying Hepatitis B Birth Dose
December 5, 2025
·
3 min read
·
Tristan Manalac
